Loading…
Loading…
MBX does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for MBX and 80,000+ other tickers.
See exactly how MBX's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for MBX and 80,000+ other tickers.
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1…
Presenting Results of Novel Product for Validation & QC of HPV Assays MISSISSAUGA, ON / ACCESS Newswire / October 19, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it will be attending IPVS 2026 and presenting results of a novel synthetic vaginal matrix designed to assist with validation and ongoing quality management of HPV molecular assays used in cervical cancer screening programs. IPVS 2026 is the 38th annual conference of the International Papillomavirus Society, taking place in Athens, Greece October 22-25, 2026.
CARMEL, Ind. and BURLINGTON, Mass.
Shares of MBX Biosciences, Inc. (NASDAQ: MBX - Get Free Report) rose 4.1% during trading on Monday. The stock traded as high as $55.93 and last traded at $55.84. 88,613 shares were traded during mid-day trading, a decline of 86% from the average session volume of 652,820 shares. The stock had previously closed at $53.63. Analyst
MBX Biosciences, Inc. is upgraded to Buy, driven by strong canvuparatide Phase 2 data and a clear path to Phase 3 success in hypoparathyroidism. Canvuparatide's once-weekly dosing and robust efficacy position MBX to challenge Yorvipath's standard-of-care status and potentially capture blockbuster revenues. MBX's early-stage obesity pipeline leverages monthly dosing and prodrug technology, targeting a massive market despite intense competition and development risk.